Pipeline

DeepNeoVx®

Neogenlogic initiates the development of personalized cancer vaccines through multi-omics data analysis of patient-derived tumor tissues. DeepNeoVx®, built on Neogenlogic’s proprietary AI systems, identifies tumor-specific neoantigens with validated immunogenicity based on next-generation sequencing and mass spectrometry data, and designs and produces therapeutic vaccines using mRNA or peptide platforms targeting these antigens. Ultimately, the vaccines administered to patients strongly activate T-cell and B-cell responses, inducing a specific immune reaction against cancer cells.

AI Pipeline

  • DeepNeo MHC
    Model Structure

    CNN

    AI Pipeline

    DeepNeo v2.0

    Development Stage

    Completed(Patented)

    Development/IP Filing

    Validation

    Validation & Release

    Service & Clinical Application

  • DeepNeo TCR
    Model Structure

    CNN

    AI Pipeline

    DeepNeo v2.0

    Development Stage

    Completed(Patented)

    Development/IP Filing

    Validation

    Validation & Release

    Service & Clinical Application

  • DeepNeo BCR
    Model Structure

    CNN

    AI Pipeline

    DeepNeo v3.0

    Development Stage

    Completed(Patented)

    Development/IP Filing

    Validation

    Validation & Release

    Service & Clinical Application

  • DeepNeo MHC+
    Model Structure

    CNN + LLM

    AI Pipeline

    DeepNeo v4.0

    Development Stage

    Under development

    Development/IP Filing

    Validation

    Validation & Release

    Service & Clinical Application

  • DeepNeo TCR+
    Model Structure

    CNN + LLM

    AI Pipeline

    DeepNeo v4.0

    Development Stage

    Under development

    Development/IP Filing

    Validation

    Validation & Release

    Service & Clinical Application

  • DeepNeo CP
    Model Structure

    CNN + LLM

    AI Pipeline

    DeepNeo v5.0

    Development Stage

    Under development

    Development/IP Filing

    Validation

    Validation & Release

    Service & Clinical Application

PCV Pipeline

  • DNV-221
    Vaccine Type

    mRNA Vaccine

    AI Pipeline

    DeepNeo v2.0

    Development Strategy

    Proprietary

    Indication

    Solid Tumor(Not disclosed)

    Development

    Pre-Clinical/Validation

    FDA IND Filing

    Clinical Trial
    (Phase I)

  • DNV-121
    Vaccine Type

    Peptide Vaccine

    AI Pipeline

    DeepNeo v2.0

    Development Strategy

    Co-development

    Indication

    Solid Tumor(Not disclosed)

    Development

    Pre-Clinical/Validation

    FDA IND Filing

    Clinical Trial
    (Phase I)

  • DNV-231
    Vaccine Type

    mRNA Vaccine

    AI Pipeline

    DeepNeo v3.0

    Development Strategy

    Proprietary

    Indication

    Solid Tumor

    Development

    Pre-Clinical/Validation

    FDA IND Filing

    Clinical Trial
    (Phase I)

  • DNV-241
    Vaccine Type

    mRNA Vaccine

    AI Pipeline

    DeepNeo v3.0

    Development Strategy

    Co-development

    Indication

    Solid Tumor

    Development

    Pre-Clinical/Validation

    FDA IND Filing

    Clinical Trial
    (Phase I)

Lead the New Standard of Cancer Treatment with Neogenlogic